Trial Profile

A Phase 1 Trial of APX-343A as Monotherapy or in Combination With Pembrolizumab to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Dec 2025 According to AptaBio Therapeutics media release, the company is scheduled to begin dosing in healthy volunteers and patients in early 2026.
19 Nov 2025 Status changed from not yet recruiting to recruiting.
18 Nov 2025 According to AptaBio Therapeutics media release, the company begins phase 1 dosing of its immunotherapy candidate, APX-343A. The company plans to use the safety and pharmacokinetic (PK) data obtained from the first cohort to accelerate future combination trials and establish a global development strategy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com